Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | DNM1L | O00429 | 3/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276163 | 0.93 | PTGER4 (0.39) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276143 | 0.93 | PTGER4 (0.39) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276176 | 0.90 | TBXA2R (0.37) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL29402821 | 0.89 | PTGER4 (0.37) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276145 | 0.89 | PTGER4 (0.37) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276147 | 0.87 | TBXA2R (0.36) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276340 | 0.87 | TBXA2R (0.36) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276032 | 0.86 | PTGER3 (0.36) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276285 | 0.85 | PTGER4 (0.37) | TBXA2RPTGER1PTGER4PTGFRPTGER3 | |
| SCHEMBL22276343 | 0.84 | PTGER4 (0.39) | TBXA2RPTGER1PTGER4PTGFRPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2025-03-04 | — | — | US | disclosed |
| EP-3889134-B1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | KEYTHERA SUZHOU PHARMACEUTICALS CO LTD (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-111989311-B | Compound for inhibiting PGE2/EP4 signal transduction, preparation method thereof and application thereof in medicines | 凯复(苏州)生物医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220064113-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3889134-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889134-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020151566-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | 凯复制药有限公司 | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064113-A1 | COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | PTGER4, PTGER1, PTGES | TBXA2R 28/4885PTGER1 2/4885PTGER4 1/4885 |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | PTGER4, PTGER1, PTGES | TBXA2R 28/4885PTGER1 2/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.